USPTO Says Arthrex Patent Do-Over Bid Could Paralyze Gov't

By Ryan Davis ( February 23, 2022, 8:05 PM EST) -- Arthrex's argument that the interim director of the U.S. Patent and Trademark Office cannot review Patent Trial and Appeal Board decisions misreads the law and would cause "paralysis" of many agencies during presidential transitions, the office told the Federal Circuit on Tuesday....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!